Phospholipid Barrier to Fibrinolysis

Balázs Váradi, Krasimir Kolev, Kiril Tenekedjiev, Gyöngyi Mészáros, Ilona Kovalszky, Colin Longstaff, Raymund Machovich

Journal of Biological Chemistry · 2004 · 20 citations · 46 references

DOIFull text

Open access

Concepts

Abstract

The massive presence of phospholipids is demonstrated in frozen sections of human arterial thrombi. Purified platelet phospholipids and synthetic phospholipids retard in vitro tissue-type plasminogen activator (tPA)-induced fibrinolysis through effects on plasminogen activation and plasmin function. The inhibition of plasminogen activation on the surface of fibrin correlates with the fraction of anionic phospholipid. The phospholipids decrease the amount of tPA penetrating into the clot by 75% and the depth of the reactive surface layer occupied by the activator by up to 30%, whereas for plasmin both of these parameters decrease by ∼50%. The phospholipids are not only a diffusion barrier, they also bind the components of the fibrinolytic system. Isothermal titration calorimetry shows binding characterized with dissociation constants in the range 0.35-7.64 μm for plasmin and tPA (lower values with more negative phospholipids). The interactions are endothermic and thermodynamically driven by an increase in entropy, probably caused by the rearrangements in the ordered gel structure of the phospholipids (in line with the stronger inhibition at gel phase temperatures compared with liquid crystalline phase temperatures). These findings show a phospholipid barrier, which should be overcome during lysis of arterial thrombi. The massive presence of phospholipids is demonstrated in frozen sections of human arterial thrombi. Purified platelet phospholipids and synthetic phospholipids retard in vitro tissue-type plasminogen activator (tPA)-induced fibrinolysis through effects on plasminogen activation and plasmin function. The inhibition of plasminogen activation on the surface of fibrin correlates with the fraction of anionic phospholipid. The phospholipids decrease the amount of tPA penetrating into the clot by 75% and the depth of the reactive surface layer occupied by the activator by up to 30%, whereas for plasmin both of these parameters decrease by ∼50%. The phospholipids are not only a diffusion barrier, they also bind the components of the fibrinolytic system. Isothermal titration calorimetry shows binding characterized with dissociation constants in the range 0.35-7.64 μm for plasmin and tPA (lower values with more negative phospholipids). The interactions are endothermic and thermodynamically driven by an increase in entropy, probably caused by the rearrangements in the ordered gel structure of the phospholipids (in line with the stronger inhibition at gel phase temperatures compared with liquid crystalline phase temperatures). These findings show a phospholipid barrier, which should be overcome during lysis of arterial thrombi. The basis of the current thrombolytic therapy in acute myocardial infarction or ischemic stroke is the administration of plasminogen activators (e.g. tPA 1The abbreviations used are: tPA, tissue-type plasminogen activator; PAI-1, plasminogen activator inhibitor-1; α2-PI, α2-plasmin inhibitor; PC, dipalmitoylphosphatidylcholine; PS, dipalmitoylphosphatidylserine; poPC, palmitoyloleoylphosphatidylcholine; BSA, bovine serum albumin; FITC, fluorescein isothiocyanate; DPH, 1,6-diphenyl-1,3,5-hexatriene; DHPS, dihexanoylphosphatidylserine; LUV, large unilamellar phospholipid vesicle; PCPS3:1, LUV containing PC and PS mixed at 3:1 weight ratio; PCPS1:1, LUV containing PC and PS mixed at 1:1 weight ratio; poPCPS, LUV containing poPC, PC and PS mixed at 2:3:5 weight ratio; poPCPS1:1, LUV containing poPC and PS mixed at 1:1 weight ratio; SPR, surface plasmon resonance; ITC, isothermal titration calorimetry. 1The abbreviations used are: tPA, tissue-type plasminogen activator; PAI-1, plasminogen activator inhibitor-1; α2-PI, α2-plasmin inhibitor; PC, dipalmitoylphosphatidylcholine; PS, dipalmitoylphosphatidylserine; poPC, palmitoyloleoylphosphatidylcholine; BSA, bovine serum albumin; FITC, fluorescein isothiocyanate; DPH, 1,6-diphenyl-1,3,5-hexatriene; DHPS, dihexanoylphosphatidylserine; LUV, large unilamellar phospholipid vesicle; PCPS3:1, LUV containing PC and PS mixed at 3:1 weight ratio; PCPS1:1, LUV containing PC and PS mixed at 1:1 weight ratio; poPCPS, LUV containing poPC, PC and PS mixed at 2:3:5 weight ratio; poPCPS1:1, LUV containing poPC and PS mixed at 1:1 weight ratio; SPR, surface plasmon resonance; ITC, isothermal titration calorimetry. and its recombinant variants), which convert the plasminogen in blood plasma or on the surface of the thrombi to plasmin and the latter dissolves fibrin, the solid matrix of thrombi (1Collen D. Lijnen H.R. Thromb. Haemostasis. 1995; 74: 167-171Crossref PubMed Scopus (93) Google Scholar). However, persistent recanalization of the occluded blood vessels often fails (in 15-40% of patients), and efficient doses of thrombolytics have significant bleeding side effects (2Verstraete M. Sasahara A.A. Loscalzo J.L. New Therapeutic Agents in Thrombosis and Thrombolysis. Marcel Dekker, Inc., New York2003: 477-478Google Scholar). The limitations of existing fibrinolytic therapy indicate that thrombolysis is not identical to fibrinolysis and direct attention to the variety of cellular and molecular factors present in thrombi that modulate the function of the basal fibrinolytic machinery (recently reviewed in Ref. 3Kolev K. Machovich R. Thromb. Haemostasis. 2003; 89: 610-621Crossref PubMed Scopus (72) Google Scholar). Platelets render thrombi resistant to lysis with tPA (4Jang I.K. Gold H.K. Ziskind A.A. Fallon J.T. Holt R.E. Leinbach R.C. May J.W. Collen D. Circulation. 1989; 79: 920-928Crossref PubMed Scopus (289) Google Scholar), which can be partially explained by their PAI-1 content (5Booth N.A. Simpson A.J. Croll A. Bennett B. MacGregor I.R. Br. J. Haematol. 1988; 70: 327-333Crossref PubMed Scopus (250) Google Scholar), but evidence for PAI-1-independent inhibition of fibrinolysis also exists (6Fay W.P. Eitzman D.T. Shapiro A.D. Madison E.L. Ginsburg D. Blood. 1994; 83: 351-356Crossref PubMed Google Scholar). When arterial thrombi are formed, the platelet content of 10 ml of whole blood is compacted in a volume of 400 μl, whereas the fibrin content of the same thrombi corresponds to the fibrinogen concentration in blood plasma (7McBane II, R.D. Ford M.A.P. Karnicki K. Stewart M. Owen W.G. Thromb. Haemostasis. 2000; 84: 83-87Crossref PubMed Scopus (22) Google Scholar), the intrathrombus plasminogen (0.4 μm), and α2-PI (0.25 μm) concentrations are just fractions of the respective plasma values (8Robbie L.A. Bennett B. Croll A.M. Brown P.A.J. Booth N.A. Thromb. Haemostasis. 1996; 75: 127-133Crossref PubMed Scopus (84) Google Scholar). After activation, the platelets release their cytosolic content and lose the majority of their phospholipid (9Skarlatos S.I. Rao R. Dickens B.F. Kruth H.S. Virchows Arch. 1993; 64: 241-245Crossref Scopus (8) Google Scholar). By taking into account the average amount of phospholipids in platelets (10Schick P.K. Colman R.W. Hirsh J. Marder V.J. Salzman E.W. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. J. B. Lippincott, Philadelphia1994: 574-589Google Scholar), the phospholipid content of arterial thrombi (7.5 g/liter) is expected to be higher than their fibrin content (1.7 g/liter). Phospholipids are known to bind fibrinogen and to modify the proteolytic susceptibility of fibrin(ogen) to thrombin and plasmin (11Cook B.C. Retzinger G.S. J. Colloid. Interface Sci. 1994; 162: 171-181Crossref Scopus (18) Google Scholar, 12Günther A. Kalinowski M. Elssner A. Seeger W. Am. J. Physiol. 1994; 267: L618-L624PubMed Google Scholar, 13Retzinger G.S. Cook B.C. DeAnglis A.P. J. Colloid. Interface Sci. 1994; 168: 514-521Crossref Scopus (35) Google Scholar, 14Retzinger G.S. Arterioscler. Thromb. Vasc. Biol. 1995; 15: 786-792Crossref PubMed Scopus (24) Google Scholar, 15Cunningham M.T. Citron B.A. Koerner T.A.W. Thromb. Res. 1999; 95: 325-334Abstract Full Text Full Text PDF PubMed Scopus (11) Google Scholar, 16Günther A. Markart P. Kalinowski M. Ruppert C. Grimminger F. Seeger W. Am. J. Respir. Cell Mol. Biol. 1999; 21: 738-745Crossref PubMed Scopus (16) Google Scholar). The contribution of the platelet phospholipids to discrete steps of blood coagulation is well characterized (reviewed in Refs. 17Zwaal R.F.A. Schroit A.J. Blood. 1997; 89: 1121-1132Crossref PubMed Google Scholar and 18Lentz B.R. Prog. Lipid Res. 2003; 42: 423-438Crossref PubMed Scopus (251) Google Scholar), but data on the functional consequences with respect to fibrinolysis are rather controversial. Higher proteolytic susceptibility to plasmin has been reported for monomeric fibrinogen layers on phospholipid surfaces (11Cook B.C. Retzinger G.S. J. Colloid. Interface Sci. 1994; 162: 171-181Crossref Scopus (18) Google Scholar), but data for inhibited degradation of fibrinogen (19Günther A. Bleyl H. Seeger W. Am. J. Physiol. 1993; 265: L186-L192PubMed Google and fibrin A. Kalinowski M. Elssner A. Seeger W. Am. J. Physiol. 1994; 267: L618-L624PubMed Google are also to the at the of the phospholipid of the in is The only in respect is the of tPA by PAI-1 M. K. H. J. Biol. Full Text PDF PubMed Google Scholar). the of a and a phospholipid on the of the in the and the phase structure of the layer interactions to and J. Biol. Full Text PDF PubMed Google Scholar). The known phospholipid of the human platelet PubMed Scopus Google both of these The platelet are by the and of with a significant fraction of anionic and The phospholipids are in the and layers of the platelet in the at activation, anionic are on the surface (reviewed in Refs. 17Zwaal R.F.A. Schroit A.J. Blood. 1997; 89: 1121-1132Crossref PubMed Google Scholar and 18Lentz B.R. Prog. Lipid Res. 2003; 42: 423-438Crossref PubMed Scopus (251) Google Scholar). The of phase structure by phospholipid at a is by the of their (reviewed in Ref. F. 1999; PubMed Scopus Google Scholar), and the contribution of to the in platelet phospholipids PubMed Scopus Google Scholar), the platelet is expected to be in the The presence of and their in the of cellular function for the of phospholipid in the phase which has been in platelets A. A. J. Biol. Full Text PDF PubMed Google and W. M. Sci. A. PubMed Scopus Google Scholar, A. A. H. H. A. Arch. 1993; PubMed Scopus Google Scholar), but can be in vitro in phospholipid with of and PubMed Scopus Google Scholar). of of platelet with respect to both and phase in vitro to their with should to discrete of the present the contribution of gel phase of PC and PS, the of which is in the range is of the the average of the temperatures at the and the of the gel to the PubMed Scopus Google Scholar). the of the phospholipid crystalline phase in interactions with of the fibrinolytic at a or by in the content of the phospholipid. The presence of poPC the of PC to and the with a of poPC is in the gel phase at and in the phase at F. 1999; PubMed Scopus Google Scholar). of with of phospholipids is that these the in (reviewed in Refs. PubMed Scopus Google Scholar and Physiol. 1995; PubMed Scopus Google Scholar). The of to at temperatures the PubMed Scopus Google Scholar), of binding A.M. PubMed Scopus Google Scholar), and of binding J. Biol. 265: Full Text PDF PubMed Google Scholar). The of are of the but they the of the discrete effects of the phospholipid plasma and platelet fibrinogen and on The plasmin and the tPA of and thrombin α2-PI, PC, PS, poPC, BSA, DPH, and used for the of human plasma PubMed Scopus Google well for the of plasmin and of its concentration K. K. Machovich R. J. Biol. 1994; Full Text PDF PubMed Google Scholar). with with to the with of of by the The to of the The of the is to that of J. P. J. PubMed Scopus Google Scholar). with a H. PubMed Scopus Google of the basis of the of the the functional of the tPA, and plasmin by plasminogen activation and fibrinolytic to K. Owen W.G. Machovich R. 1995; PubMed Scopus (22) Google Scholar, K. Owen W.G. Machovich R. Thromb. Haemostasis. 1996; 75: PubMed Scopus Google Scholar). of PS, and poPC mixed at the and in volume of the the phospholipids with for with a in 10 containing in which and with through a in a Inc., R.C. K. PubMed Scopus Google Scholar). The concentration of phospholipids in the LUV with the P. C. J. B. PubMed Scopus Google Scholar). of human platelet to the lysis J.T. PubMed Scopus Google Scholar). the the platelets for and fraction used a platelet The phospholipids the with with for at The fraction the of the the in and their phospholipid content for the synthetic phospholipids of platelet ml of containing K. Owen W.G. Machovich R. Thromb. Haemostasis. 1996; 75: PubMed Scopus Google Scholar). of μm fibrinogen containing or μm plasminogen and the at concentrations with thrombin in at for The of the by of tPA on the surface of the and of the to The of clot and by the at at or with a The lysis the to the of the clot to used a of fibrinolytic activation in K. Owen W.G. Machovich R. 1995; PubMed Scopus (22) Google Scholar). μm plasminogen containing the at concentrations mixed with at and the of the plasmin on activation in the presence of fibrin on the surface of fibrin C. J. Thromb. PubMed Scopus Google in of 10 thrombin and of μm fibrinogen in 10 containing μm and the at After of at of tPA in and on the clot surface by of The at the release of by the plasmin with a at The values are a with a to the of plasminogen activation M. PubMed Scopus Google Scholar). of the for the of by by concentrations of plasmin and α2-PI K. K. Machovich R. J. Biol. 1994; Full Text PDF PubMed Google in the and presence of of into the depth of the reactive fibrin in by fibrinogen in and or with thrombin for or (in the same containing to the of the and the with the taking of the at a of μm the surface with identical and to of the for The of the into which the on the with the amount of fibrin of volume and the same in (in of containing to the surface of the and for diffusion and at the of which the phase the clot than of the fibrin surface with of of which the the and the The of with a 400 By data and the known in the the amount of tPA or plasmin in the clot of to with fibrin and K. K. Machovich R. J. Biol. 1994; Full Text PDF PubMed Google Scholar). of 10 with or to the surface in the and the presence of concentrations After 10 of at the and the (in than 10 with of A. of and the of g/liter) mixed with or μm) in and and for at of at in an Inc., for The amount of in the of the phospholipid be with the in of phospholipids and with on M. P. 1994; PubMed Scopus Google Scholar). matrix with used to phospholipid whereas used to a phospholipid to the Isothermal the of phospholipids and isothermal titration on Inc., 1989; PubMed Scopus Google Scholar, 1995; PubMed Scopus Google Scholar). The in a of into the of the containing and the of by the of into in a of and these the data than the titration of into only for the of plasmin at The data the of into LUV to the PubMed Scopus Google with of Phospholipids with sections of thrombi with by at the of human for phospholipids J.L. J. Google Scholar). of with by of in used to the and the sections in 10 in for with and with The phospholipids with fibrin fibrinogen containing with 10 thrombin for at and these and with the same phospholipids not of thrombi human shows massive presence of phospholipids The of the phospholipid in the sections is with that in the fibrin containing phospholipid. The of the phospholipid to the of When the of platelet on fibrin is in significant is which at can be explained with the known PAI-1 content of platelets (5Booth N.A. Simpson A.J. Croll A. Bennett B. MacGregor I.R. Br. J. Haematol. 1988; 70: 327-333Crossref PubMed Scopus (250) Google Scholar). However, at the platelet not the of plasmin by tPA in a in the fibrinolytic is partially by platelet or synthetic at identical phospholipid concentrations and is with higher phospholipid of the clot The of inhibition at The is at phospholipid concentration of but DHPS, which not is used in the fibrinolytic of inhibition of the is at concentrations up to The of is to the of α2-PI present in the fibrin and these are in the fibrinolytic the of plasmin by α2-PI in the presence of phospholipids in a of phospholipids on the inhibition of fibrinolysis by containing μm plasminogen have been with the α2-PI α2-PI and tPA is on the and data are at and in inhibition of plasmin by α2-PI in the of and α2-PI are mixed at concentrations at in a volume of containing or the of is and the plasmin the and of show the of the K. K. Machovich R. J. Biol. 1994; Full Text PDF PubMed Google Scholar), with of in the of phospholipid and in the presence of The of the effects be inhibition of plasminogen activation or plasmin When plasminogen activation is in or of synthetic by plasmin is the presence of to g/liter) not the of the However, the are in the solid phase fibrin and plasmin is on its the of plasminogen activation The of inhibition correlates with the fraction of anionic phospholipid in the the is used in plasminogen activation of inhibition of the is of the with a in the of into fibrin shows that an reactive layer of is the of the tPA of the presence of phospholipid When is present in the fibrin the depth of into which the tPA μm μm in the of PCPS3:1, not the of the layer is to the surface of fibrin, both and the of the reactive layer to and the of the occupied by tPA or plasmin is an of the fibrinolytic the of the on their concentration in the reactive of the tPA and plasmin that phospholipids the amount of penetrating to a than the of the reactive with a on the anionic of their The of plasminogen is only by the with anionic The of diffusion is the same in with of of into with PC or the at phospholipid concentration have been of or in containing are on the surface of the After the layer is the surface is and the is The the and values of is the amount of respective in of or is to fibrin on a 10 of and and of the respective to the the binding is in the presence of concentrations of a decrease in the fraction of is with a of inhibition at and of is on the the the amount of of of and of to and The effects of the phospholipid on the surfaces indicate with the phase rather than with the fibrin or more direct have been to these of at a are the same the amount of in the fraction of that has not the and their with are of plasmin of to the fraction in the of whereas of plasminogen the of not be with tPA, of the of tPA in the of The of of phospholipids with of the fibrinolytic with and The plasmin binding to both of on the surface of the and on the of the with dissociation constants of and These data are in line with the the titration calorimetry and for at that the of phospholipid the binding for a is by the data for The plasmin binding only to the of with a of whereas evidence for with its but with values an of higher than with the of the titration the of interactions that only on the phospholipid to the The data on the interactions of tPA and plasminogen with phospholipids are in line with tPA only on the whereas the binding to with a of μm and to with a of not on of the phospholipid but interactions values of μm for and μm for The for of the binding and only for the interactions with the and The for the interactions can be to the of the When of are to the the layer is the but the with the layer is the surface on is but the of the surface in and parameters of the of plasmin with in a of plasmin with The in in the and plasmin in the at and The of the of the that can be plasmin is in at of arterial thrombi the presence of phospholipids with with that of phospholipid in fibrin the of phospholipids on fibrinolysis in an that the of arterial thrombi with respect to fibrin μm), plasminogen μm), and α2-PI μm) content (7McBane II, R.D. Ford M.A.P. Karnicki K. Stewart M. Owen W.G. Thromb. Haemostasis. 2000; 84: 83-87Crossref PubMed Scopus (22) Google Scholar, L.A. Bennett B. Croll A.M. Brown P.A.J. Booth N.A. Thromb. Haemostasis. 1996; 75: 127-133Crossref PubMed Scopus (84) Google Scholar). The tPA concentrations are higher than the basal in human plasma (8Robbie L.A. Bennett B. Croll A.M. Brown P.A.J. Booth N.A. Thromb. Haemostasis. 1996; 75: 127-133Crossref PubMed Scopus (84) Google Scholar), but of the plasma of tPA in the of thrombolytic therapy concentrations F. Colman R.W. Hirsh J. Marder V.J. Salzman E.W. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. J. B. Lippincott, Philadelphia1994: Scholar). The concentration range g/liter) of phospholipids is than the values the platelet content (7McBane II, R.D. Ford M.A.P. Karnicki K. Stewart M. Owen W.G. Thromb. Haemostasis. 2000; 84: 83-87Crossref PubMed Scopus (22) Google or phospholipid of arterial thrombi but amount of phospholipids is to the on fibrinolysis the concentrations of fibrinolytic are to the of arterial phospholipid the platelet in inhibition of the fibrinolysis with the of platelet phospholipids and identical to the inhibition by the synthetic the of platelet in the the tPA concentration used is to the expected PAI-1 in the with the (8Robbie L.A. Bennett B. Croll A.M. Brown P.A.J. Booth N.A. Thromb. Haemostasis. 1996; 75: 127-133Crossref PubMed Scopus (84) Google Scholar). The of on fibrinolysis is to the of α2-PI present in the clot a concentration higher than the average for α2-PI content in arterial thrombi (8Robbie L.A. Bennett B. Croll A.M. Brown P.A.J. Booth N.A. Thromb. Haemostasis. 1996; 75: 127-133Crossref PubMed Scopus (84) Google Scholar). phospholipids the inhibition of plasmin by α2-PI the presence of and α2-PI stronger inhibition in the fibrinolytic than of the that the phospholipids the well known of plasmin its on the fibrin surface K. K. Machovich R. J. Biol. 1994; Full Text PDF PubMed Google Scholar). line with findings A. Kalinowski M. Elssner A. Seeger W. Am. J. Physiol. 1994; 267: L618-L624PubMed Google Scholar, A. Bleyl H. Seeger W. Am. J. Physiol. 1993; 265: L186-L192PubMed Google Scholar), phospholipids also retard the of fibrin with plasmin on the surface of the clot The of a plasminogen activation that plasmin on the surface of fibrin that the of fibrinolysis is at partially on the inhibition of plasminogen activation activation in the of phospholipids have the that the of thrombolytics should be in that the in thrombi. for the of phospholipids on the fibrinolytic the presence of anionic and The plasminogen activation shows the of inhibition and the fraction of anionic phospholipid in the The data on the binding of plasmin and tPA to phospholipids are in line with the of the anionic of more plasmin the than the The values of the dissociation constants of both plasmin and tPA indicate an of higher to than to The is not a for the phospholipid the anionic is used in the functional at higher concentrations than the the fibrin the plasminogen activation is only the but also the of is The ordered gel structure PC and PS and a PubMed Scopus Google the fibrinolysis at the is in the structure at temperatures the the is demonstrated for and a than F. 1999; PubMed Scopus Google in The with and a of F. 1999; PubMed Scopus Google fibrinolysis at stronger on the gel phase side of the and on the liquid crystalline side line with the gel phase and expected the of the platelet PubMed Scopus Google Scholar), the platelet phospholipids fibrinolysis at the of gel phase in the platelet is probably to the presence of which to the of with A. A. J. Biol. Full Text PDF PubMed Google Scholar, W. M. Sci. A. PubMed Scopus Google Scholar, A. A. H. H. A. Arch. 1993; PubMed Scopus Google Scholar, PubMed Scopus Google Scholar). is in with the on the effects of the platelet which fibrinolysis to a at and but the are the phospholipids the only at the The phase structure the of fibrin and the of with inhibition A. Kalinowski M. Elssner A. Seeger W. Am. J. Physiol. 1994; 267: L618-L624PubMed Google Scholar, A. Bleyl H. Seeger W. Am. J. Physiol. 1993; 265: L186-L192PubMed Google Scholar), whereas with phospholipid (11Cook B.C. Retzinger G.S. J. Colloid. Interface Sci. 1994; 162: 171-181Crossref Scopus (18) Google Scholar). the gel phase at a is to the fraction of in the phospholipid the of in platelet be an to the effects of in The of the more their effects on the of the J. Biol. Full Text PDF PubMed Google Scholar). The data on the of the gel phase the the interactions of and tPA with are endothermic and and these are thermodynamically in The increase in is probably caused by the rearrangements in the ordered gel structure of the However, the phospholipid is in the liquid crystalline the interactions are thermodynamically (in line with the of The for the that the phospholipid in the of the fibrin gel and the of is by the data on the of the reactive layer and the amount of The anionic decrease the amount of tPA in the clot to of the in the of and the activator a layer on the fraction of anionic the depth in The of plasmin is also by anionic both the amount of in the clot and the occupied layer decrease by ∼50%. The phospholipids are not only a diffusion barrier, they also bind the components of the fibrinolytic and The of the binding is characterized by values in the range μm for plasmin and tPA (lower values for the more negative and an of higher dissociation constants for The in the binding parameters on phospholipid and that the of the surface be an in the interactions with of the large of the binding of phospholipid for tPA, and which corresponds to an of G.S. PubMed Scopus Google Scholar). should be that have not direct of the for the binding of fibrinolytic factors to and the latter direct is not can be a of which surface or the in platelet and their are in thrombi. probably the parameters of the interactions the range by the values these The binding of fibrinolytic components to phospholipids for the thrombi and that plasminogen is to Thromb. Haemostasis. PubMed Scopus Google Scholar). phospholipids with fibrin for the binding fibrinolytic components and retard in their The parameters in are with the dissociation constants of fibrin with plasminogen μm), plasminogen μm), or tPA μm) Ref. J. Biol. Full Text PDF Google Scholar and reviewed in Ref. W. Thromb. Haemostasis. 2003; 89: PubMed Scopus Google Scholar). the plasma of plasminogen μm) the of phospholipids be of for plasmin phospholipids components for the PAI-1-independent inhibition of fibrinolysis (6Fay W.P. Eitzman D.T. Shapiro A.D. Madison E.L. Ginsburg D. Blood. 1994; 83: 351-356Crossref PubMed Google Scholar), of and the to thrombolytics that into the by the phospholipids or the phospholipid in arterial thrombi. are to for

References

46